Table 5.
Joint effect of HPV16 L1 seropositivity and MDM2 genotypes on risk stratified by tumor site in patients and controls recruited from The University of Texas MD Anderson Cancer Center and general hospitals in Houston between 1996 and 2002
| HPV16 status | MDM2 genotypes | Oropharynx | Oral cavity | ||
|---|---|---|---|---|---|
| Pa/Co (188/335) | Adj. OR (95% CI)* | Pa/Co (137/335) | Adj. OR (95% CI)* | ||
| MDM2-rs2279744 | |||||
|
| |||||
| − | GT/GG(Ref.) | 50/195 | 1.00 | 78/195 | 1.00 |
| − | TT | 51/98 | 2.06 (1.29–3.29) | 46/98 | 1.23 (0.78–1.94) |
| + | GT/GG | 42/28 | 5.37 (3.00–9.60) | 9/28 | 0.82 (0.36–1.85) |
| + | TT | 45/14 | 12.6 (6.37–25.1) | 4/14 | 0.79 (0.25–2.53) |
|
| |||||
| MDM2-rs937283 | |||||
|
| |||||
| − | AA (Ref.) | 25/97 | 1.00 | 24/97 | 1.00 |
| − | AG/GG | 76/196 | 1.62 (0.96–2.73) | 100/196 | 2.18 (1.29–3.69) |
| + | AA | 16/17 | 3.30 (1.44–7.54) | 4/17 | 0.94 (0.28–3.12) |
| + | AG/GG | 71/25 | 11.5 (6.03–22.1) | 9/25 | 1.68 (0.67–4.20) |
|
| |||||
| MDM2 combined genotypes | |||||
|
| |||||
| − | Low risk group (Ref.)a | 21/82 | 1.00 | 21/82 | 1.00 |
| − | Medium risk group | 33/128 | 1.11 (0.59–2.07) | 60/128 | 1.98 (1.10–3.57) |
| − | High risk group | 47/83 | 2.37 (1.29–4.36) | 43/83 | 2.20 (1.18–4.12) |
| + | Low risk group | 11/13 | 2.99 (1.15–7.77) | 4/13 | 1.26 (0.36–4.41) |
| + | Medium risk group | 36/19 | 7.30 (3.45–15.4) | 5/19 | 1.05 (0.34–3.25) |
| + | High risk group | 40/10 | 17.2 (7.26–40.7) | 4/10 | 2.05 (0.57–7.42) |
Pa/Co: Patients/Controls
*
ORs were adjusted for age, sex, smoking, and alcohol drinking.
a
Low-risk group: MDM2-rs2279744 G carriers and MDM2-rs937283 AA genotype; Medium-risk group: MDM2-rs2279744 G carriers and MDM2-rs937283 G carriers or MDM2-rs2279744 G TT and MDM2-rs937283 AA genotypes; and High-risk group: MDM2-rs2279744 TT and MDM2-rs937283 G carriers.